Neurotoxicity after orthotopic liver transplantation in cyclosporin A- and FK 506-treated patients
- PMID: 11271254
- DOI: 10.1111/j.1432-2277.1994.tb01307.x
Neurotoxicity after orthotopic liver transplantation in cyclosporin A- and FK 506-treated patients
Abstract
Neurotoxicity is a serious complication following orthotopic liver transplantation leading to increased morbidity and mortality. Neurotoxicity may be evoked by various perioperative factors, or may be due to drug-specific toxicity of immunosuppression. In the present study we evaluated the incidence of central nervous system (CNS) toxicity occurring within the early postoperative period of 121 patients, 61 randomly assigned to FK 506- and 60 to CsA-based immunosuppression as part of a multicentre study. The incidence of moderate or severe CNS toxicity was higher in patients treated with FK 506 (21.3%) than in patients receiving CsA (11.7%). The duration of symptoms was also greater in patients treated with FK 506 than in patients receiving CsA. The incidence of moderate or severe neurotoxicity after retransplantation was markedly greater in patients treated with FK 506 (100% of the patients).
Similar articles
-
Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients.Transpl Int. 1994;7 Suppl 1:S52-7. doi: 10.1111/j.1432-2277.1994.tb01310.x. Transpl Int. 1994. PMID: 11271297 Clinical Trial.
-
Neurological complications in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation.Transpl Int. 1994;7 Suppl 1:S27-31. doi: 10.1111/j.1432-2277.1994.tb01305.x. Transpl Int. 1994. PMID: 11271222 Clinical Trial.
-
Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506.Transplantation. 1994 Jul 27;58(2):155-70. Transplantation. 1994. PMID: 7518974 Clinical Trial.
-
Clinical use of FK 506 in liver transplantation.Transplant Proc. 1996 Apr;28(2):974-6. Transplant Proc. 1996. PMID: 8623484 Review.
-
Neoral is superior to FK 506 in liver transplantation.Transplant Proc. 1998 Aug;30(5):1812-5. doi: 10.1016/s0041-1345(98)00442-4. Transplant Proc. 1998. PMID: 9723293 Review. No abstract available.
Cited by
-
Cognitive Evaluation in Liver Transplant Patients Under Calcineurin Inhibitor Maintenance Therapy.Transplant Direct. 2017 Mar 28;3(4):e146. doi: 10.1097/TXD.0000000000000658. eCollection 2017 Apr. Transplant Direct. 2017. PMID: 28405602 Free PMC article.
-
Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis.Cochrane Database Syst Rev. 2017 Mar 31;3(3):CD011639. doi: 10.1002/14651858.CD011639.pub2. Cochrane Database Syst Rev. 2017. PMID: 28362060 Free PMC article.
-
Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I).J Transl Med. 2011 Jul 28;9:124. doi: 10.1186/1479-5876-9-124. J Transl Med. 2011. PMID: 21798013 Free PMC article. Clinical Trial.
-
Evaluation of Tacrolimus' Adverse Effects on Zebrafish in Larval and Adult Stages by Using Multiple Physiological and Behavioral Endpoints.Biology (Basel). 2024 Feb 10;13(2):112. doi: 10.3390/biology13020112. Biology (Basel). 2024. PMID: 38392330 Free PMC article.
-
The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence.J Transplant. 2014;2014:845438. doi: 10.1155/2014/845438. Epub 2014 Feb 25. J Transplant. 2014. PMID: 24719752 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical